Bone marrow cells are used for cell therapy after myocardial infarction (MI) with promising results. However, cardiac persistence of transplanted cells is rather low. Here, we investigated strategies to increase the survival and cardiac persistence of mononuclear (MNC) and mesenchymal (MSC) bone marrow cells transplanted into infarcted rat hearts. MNC and MSC (male Fischer 344 rats) were treated with different doses of PDGF-BB prior to intramyocardial injection into border zone of MI (syngeneic females, permanent LAD ligation) and hearts were harvested after 5 days and 3 weeks. In additional experiments, untreated MNC and MSC were injected immediately after permanent or temporary LAD ligation and hearts were harvested after 48 h, 5 days, 3 weeks, and 6 weeks. DNA of the hearts was isolated and the number of donor cells was determined by quantitative real-time PCR with Y chromosome-specific primers. There was a remarkable though not statistically significant (p = 0.08) cell loss of ϳ46% between 5 days and 3 weeks in the control group, which was completely inhibited by treatment with high dose of PDGF-BB. Forty-eight hours after reperfusion only 10% of injected MSC or 1% for MNC were found in the heart, decreasing to 1% for MSC and 0.5% for MNC after 6 weeks. These numbers were lower than after permanent LAD ligation for both MNC and MSC at all time points studied. Treatment with PDGF-BB seems to prevent loss of transplanted bone marrow cells at later times presumably by inhibition of apoptosis, while reperfusion of the occluded artery enhances cell loss at early times putatively due to enhanced early wash-out. Further investigations are needed to substantially improve the persistence and survival of grafted bone marrow cells in infarcted rat hearts, in order to fully explore the therapeutic potential of this novel treatment modality for myocardial repair.
INTRODUCTION
chymal bone marrow cells within the infarcted rat heart decreases rapidly to only a few percent of the originally transplanted cell number at 6 weeks after intramyocari-Cardiac cell therapy with bone marrow cells after myocardial infarction was demonstrated to improve car-dal cell injection (7) . The aim of this study was to increase the midterm survival by either cell treatment with diac function in several large randomized clinical trials (12, 17) , but, on the other hand, there was no benefit the growth factor and inhibitor of apoptosis PDGF-BB prior to transplantation or reperfusion of the infarcted observed in other studies (4, 5, 10) . Although it is still unknown how bone marrow cells take action on cardiac vessel (improved nutrient and oxygen supply of the cells). regeneration, the number of transplanted cells within the MATERIALS AND METHODS injured myocardium is likely to be an important factor. In previous studies, we showed that after a good engraft-Protocols were approved by the regional government's Animal Care and Use Committee (Bezirksregier-ment efficacy the number of mononuclear and mesen-848 KRAUSGRILL ET AL.
ung Köln, No. 50.203.2-K47, 34/03, and 50.203.2-K47, coronary artery under ketamine and xylazine anesthesia as described previously (9) . LAD ligation was either 2/03), and conformed with the Guide for the Care and Use of Laboratory Animals of the NIH. permanent or temporary (i.e., for 30 min). Animals of the reperfusion group received an IP injection of 10 IU Bone Marrow Cell Isolation From Male Rats heparin prior to surgery in order to prevent thrombosis during LAD occlusion. Infarction was evidenced by pal-After dissecting femurs, humeral and tibial bones (male Fischer 344 rats, 2 months old, Charles River, ing of left ventricular wall, which disappeared with reperfusion. Immediately after infarction or infarction/re-Sulzfeld, Germany) from surrounding muscle and connective tissue, the bone marrow was eluted with a 19-perfusion 50 µl of cell suspension containing either 100,000 (for experiments on PDGF treatment) or 1,000,000 gauge needle and DMEM, high glucose, 10% FCS, 1% penicillin/streptomycin. The cell suspension was filtered cells (for experiments comparing permanent and reperfused myocardial infarction) were injected into the bor-through 70-µm filters, centrifuged, and resuspended in PBS. For recovery of mesenchymal bone marrow cells der zone of the myocardial infarct with three separate injections using a Hamilton syringe (H. Faust GmbH, (MSC), 50 × 10 6 bone marrow cells were plated on 10cm dishes and kept in culture for 10 days. At day 10
Rheinbach, Germany) attached to a 29-gauge needle. The higher cell number in the reperfusion experiments MSC were detached with Trypsin/EDTA, washed, and resuspended (DMEM, no FCS) at a concentration of was chosen because of the unexpectedly high cell loss we observed already in preliminary experiments. After 100,000 cells/50 µl (for experiments on PDGF treatment) or 1,000,000 cells/50 µl (for experiments comparing per-cell therapy, rats were allowed to survive for 48 h, 5 days, 3 or 6 weeks. manent and reperfused myocardial infarction). For isolation of mononuclear cells, the crude bone marrow cell Treatment With PDGF-BB In Vivo suspension was subjected to a Ficoll gradient centrifugation (NycoPrep, Progen GmbH, Heidelberg, Germany).
Prior to surgery PDGF-BB was added to the suspension of MNC or MSC resulting in a concentration of 10 The interphase cells were collected, washed, and kept in suspension (DMEM, no FCS) until use (12 h at 4°C).
or 50 ng/ml. After 10 min of incubation at room temperature the whole suspension was injected as described Treatment With PDGF-AA and PDGF-BB In Vitro above. For in vitro studies, MSC of five animals were iso-DNA Preparation and Quantitative Analysis lated as described above and the cells of each animal of Cell Survival by Real-Time PCR were portioned out and kept in culture under six different conditions. A Cell Death Detection ELISA (Roche Genomic DNA preparation and quantitative real-time PCR analysis of cell survival in the heart was performed Diagnostics, Basel, Switzerland) was used to measure cell death by the detection of cytoplasmic histone-asso-as described previously with primers against the Sry genes (male genomes) and osteopontin as internal stan-ciated DNA fragments (mono-and oligonucleosomes). Cells (5,000 cells/well) were plated into 96-well dard (to normalize for the amount of DNA) (9) . Samples with known dilutions of male with female DNA were plates in DMEM containing 10% FCS followed by serum deprivation (conditions 1-6). Stimulation with PDGF-included to verify consistency and to derive a calibration curve for the calculation of male/total DNA ratio. Dur-AA (50 ng/ml, condition 2; +AA) or PDGF-BB (50 ng/ ml, condition 3; +BB) was compared to unstimulated starv-ing this technique's establishment, Y chromosome signal from dead male cells was investigated as a time ing for 24 h (condition 1; control). Apoptosis was intensified by adding H 2 O 2 (100 µM) after 24 h of unstimu-course and showed a loss of signal within several hours (9) . Additionally, to ensure that Y chromosome signal lated starving and incubation for another 15 h (conditions 4-6; +H 2 O 2 ) in the absence (condition 4; +H 2 O 2 ) or pres-does arise from intact cells, we used gold and dye labeling techniques to track the injected cells in a related ence of PDGF-AA (50 ng/ml, condition 5; +H 2 O 2 +AA) or PDGF-BB (50 ng/ml, condition 6; +H 2 O 2 +BB). The study without reperfusion and we found good correlation between the time course of cell loss resulting from our cell lysates were collected, and apoptosis was measured using the Cell Death Detection ELISA with each condi-PCR analysis and that resulting from semiquantitative histological analysis (data not shown). For the calcula-tion's optical density data being normalized to its respective unstimulated starving control experiment.
tion of absolute cell number in the heart, the male DNA/ total DNA ratio (as obtained from PCR) was multiplied Myocardial Infarction in Female Rats by the total number of nuclei in the hearts analyzed. The and Cell Injection latter number was calculated from the heart wet weight and the number of 217,400 cells in rat heart per milli-Myocardial infarction was induced in female syngeneic adult rats (2-3 months old) by ligation of the left gram wet weight as observed by van der Laarse et al. (14). This mode of analysis was previously validated in ther analysis. Treatment with PDGF-BB did not change the number of detectable male cells 5 days after LAD several models (7) (8) (9) .
ligation and cell transplantation, neither with the lower Statistical Analysis dose of 10 ng/ml (121 ± 44% with PDGF-BB vs. 100 ± All data are presented as mean ± SEM. Statistical 16% without, p = 0.66) nor with the higher dose of 50 analysis was performed with the help of computerized ng/ml (101 ± 40% with PDGF-BB vs. 100 ± 16% withcalculations with InStat (GraphPad Software Inc., out, p = 0.98). At day 21 the number of persisting cells USA) and SPSS (SPSS Inc., USA) using Student's twas decreased to 54 ± 18% of the 5 days value in the test with correction for multiple comparisons and onecontrol group (p = 0.08 vs. control at 5 days). After way ANOVA for unpaired values. A value of p < 0.05 treatment with low-dose PDGF-BB (10 ng/ml) 79 ± was considered significant.
30% and after high-dose PDGF-BB (50 ng/ml) 108 ± 34% of the 5 day control were detected (p = 0.54 and RESULTS p = 0.83 vs. control at day 5, respectively) ( Fig. 2) .
Treatment With PDGF-AA and PDGF-BB In Vitro
Reperfusion With H 2 O 2 added to standard cell culture conditions For both MNC and MSC, there were lower numbers apoptosis of cultured MSC was 2.6 ± 0.2-fold higher of transplanted cells detected in reperfused than in percompared to control (p = 0.0001). Addition of PDGFmanent myocardial infarction at all time points studied. AA to the medium did not change the rate of apoptosis For MNC, after reperfusion only 1.1 ± 0.5% of injected in cultured MSC, neither in standard cell culture condicells were detected in the heart after 48 h and 1.1 ± 0.2% tions (0.9 ± 0.3 with PDGF-AA vs. 1.0 without, p = after 5 days, which was significantly lower than in per-0.82) nor in the presence of apoptosis-inducing H 2 O 2 manent MI with 5.6 ± 0.6% after 48 h (p = 0.0006) and (3.1 ± 1.2 with PDGF-AA vs. 2.6 ± 0.2 without, p = 6.8 ± 2.2% after 5 days (p = 0.02). At later time points, 0.73). In contrast, the addition of PDGF-BB resulted in numbers were still lower after reperfusion but this difa lower rate of apoptosis in standard cell culture condiference was no longer statistical significant: 0.2 ± 0.1% tions (0.6 ± 0.1 with PDGF-BB vs. 1.0 without, p = at 3 weeks after reperfusion versus 1.6 ± 0.9% in perma-0.004) and in the presence of H 2 O 2 (0.9 ± 0.2 with nent MI (p = 0.18) and 0.2 ± 0.1% at 6 weeks after re-PDGF-BB vs. 2.6 ± 0.2 without, p = 0.004), reducing perfusion versus 1.2 ± 0.6% in permanent MI (p = 0.15). the rate of apoptosis to the same level as under control
The differences between MNC numbers in permanent conditions without H 2 O 2 (0.9 ± 0.2 with H 2 O 2 and and reperfused MI were stable for all time points stud-PDGF-BB vs. 1.0 without, p = 0.53) (Fig. 1) .
ied. At 48 h there were 80.3% less MNC detectable after Treatment With PDGF-BB In Vivo reperfusion than in permanent MI, ranging to 83.3% after 5 days, 88.4% after 3 weeks, and 80.7% after 6 As the changes in cell survival after treatment with PDGF-BB prior to cell injection were similar in MNC weeks. Also for MSC, the numbers of persisting cells were lower after reperfusion than in permanent MI at and MSC, the data of both groups were pooled for fur- all time points, although without statistical significance man umbilical cord blood mononuclear cells, which contain hematopoietic and mesenchymal stem cells (2). (Table 1, Fig. 3) .
In our previous studies, we demonstrated that midterm DISCUSSION survival of MNC and MSC bone marrow cells injected into the peri-infarct region in rats is very low (7) . Here, The number of cells successfully implanted into the injured heart and their persistence within the heart might we evaluated two strategies to increase cardiac cell persistence (and/or survival) of MNC and MSC: 1) cell be major limiting factors for cardiac cell therapy. For example a dose dependency was shown for the decrease treatment with antiapoptotic PDGF-BB prior to transplantation and 2) reperfusion of the infarcted artery. of infarct size in a rat model after transplantation of hu-PDGF-BB was used as an antiapoptotic agent. In vival curves in reperfused hearts run parallel to those in nonreperfused hearts, indicating that those cells that multiple previous studies it has been proven to protect several cell types from death (1, 11, 15, 16) . In our in vitro initially persist in the reperfused heart share the same fate with those that initially persist in the nonreperfused experiments, PDGF-AA and PDGF-BB were investigated because both are known to play different roles in hearts. In previous studies using neonatal rat cardiomyocytes, we found that cell persistence was much lower healing myocardial infarction (19) and might therefore show differences in antiapoptotic effects as well. Our when cells were injected into healthy myocardium (9) than when cells were injected into chronic infarcts (8) , results showed that PDGF-BB, but not PDGF-AA, was able to prevent apoptosis in vitro, suggesting that the and we could show that wash-out is crucial even after intracoronary infusion in stop-flow technique as used in selective activation of PDGF-receptor-α by PDGF-AA does not, but unselective activation of both PDGF-clinical trials (13). Therefore, healthy and/or reperfused tissue with reduced tissue damage and intracoronary ap-receptor-α and PDGF-receptor-β by PDGF-BB does lead to antiapoptotic effects. Therefore, these effects plication may be disadvantegous for the persistence of grafted cells. might be mediated by the PDGF-receptor-β alone.
In vivo, no statistically significant change in the num-From our data on the influence of pretreatment with PDGF-BB and reperfusion on cardiac persistence of in-ber of surviving MNC and MSC was observed, even though a remarkable cell loss of ϳ46% in the untreated jected bone marrow cells, it can be concluded that early after cell injection (up to 5 days) wash-out is the pre-control group between day 5 and day 21 was completely inhibited by treatment with high-dose PDGF-BB. Thus, dominant mechanism of cell loss (promoted by reperfusion) while later after cell injection cell death is more cell loss at later times, but not early cell loss, may be prevented by the antiapoptotic effect of high-dose important (prevented by treatment with PDGF-BB). This conclusion, albeit not very surprising, is supported by PDGF-BB on transplanted cells. Therefore, cell death rather than cell wash-out might be the predominant quantitative analyses of cell survival for the first time.
In summary, this study demonstrates that effective mechanism of cell loss at this time. Improved survival might result in improved functional benefit after treat-strategies to improve cardiac persistence of MNC and MSC are difficult to identify. The only successful ap-ment, as suggested by previous data from Mangi et al. (6) . Overexpression of antiapoptotic Akt was also effec-proaches thus far were the increase in injected cell number (which increased absolute, but not relative, cell sur-tive to reduce death of neonatal cardiomyocytes injected into infarcted hearts (18), while pretreatment with the vival) (7) and, in trend, the pretreatment of cells with PDGF-BB. The other strategies, which we have studied caspase inhibitor AcYVADcmk was not (9) . Hsieh et al. established a model of PDGF-BB-releasing nanofibers so far, have failed to enhance cardiac cell persistence, which are injection of cells late (7 days) after infarction whose injection lead to decreased cardiomyocyte death, improved cardiac function, and decreased infarct size (7) and injection of cells in infarcted/reperfused myocardium. In conclusion, further investigations are needed after myocardial infarction in rats (3). Maybe combining this constant release of PDGF-BB with cell application to substantially improve the persistence and survival of grafted bone marrow cells in infarcted rat hearts, in or-might multiply beneficial effects of both therapies. Nevertheless, it has to be noted that, although cell persis-der to fully explore the therapeutic potential of this novel treatment modality for myocardial repair. tence was almost doubled by treatment with PDGF-BB in the present study, cell survival at 21 days is still low ACKNOWLEDGMENTS: The authors are grateful to Ruth (5-7% of the initially injected cells).
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Our second approach for improvement of cell persis- role at early times. In contrast, after day 2 the cell sur-
